International audienceObjective: To compare oral anticoagulant treatment (fluindione) started on either the 1st or the 10th day of a low-molecular-weight heparin (enoxaparin) treatment for deep vein thrombosis confirmed by venography. Design: An open, multicenter, randomized study in two parallel treatment groups. Interventions: All patients received enoxaparin, 1 mg/kg s.c. twice daily, and oral fluindione, 20 mg once daily, either beginning on day 1 or on day 10 of the enoxaparin treatment. Enoxaparin was discontinued once the international normalized ratio under fluindione was stable between 2.0 and 3.0 over 2 days. Fluindione treatment was maintained during a 3-month follow-up period. Outcome Measurements: Specific examinations (venogra...
Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard ...
BACKGROUND: Vitamin K antagonists, the current standard treatment for prophylaxis against stroke and...
International audienceBACKGROUND: After stopping a 3 to 6 months course of oral anticoagulation for ...
International audienceObjective: To compare oral anticoagulant treatment (fluindione) started on eit...
International audienceBACKGROUND: Venous thromboembolism is treated with unfractionated heparin or l...
Background: The current standard initial therapies for deep venous thrombosis are low-molecular-weig...
International audienceBACKGROUND: Treatment of pulmonary embolism with low-molecular-weight heparin ...
Background: Treatment of deep-vein thrombosis (DVT) with a once-daily regimen of enoxaparin, rather ...
In the last 4 years, 6 phase 3 trials including a total of 27,023 patients with venous thromboemboli...
International audienceBACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fi...
International audienceBACKGROUND: Apixaban, an oral potent reversible direct inhibitor of activated ...
AbstractPurpose: The primary objective of this study was to evaluate with venography the rate of thr...
Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard ...
BACKGROUND: Vitamin K antagonists, the current standard treatment for prophylaxis against stroke and...
International audienceBACKGROUND: After stopping a 3 to 6 months course of oral anticoagulation for ...
International audienceObjective: To compare oral anticoagulant treatment (fluindione) started on eit...
International audienceBACKGROUND: Venous thromboembolism is treated with unfractionated heparin or l...
Background: The current standard initial therapies for deep venous thrombosis are low-molecular-weig...
International audienceBACKGROUND: Treatment of pulmonary embolism with low-molecular-weight heparin ...
Background: Treatment of deep-vein thrombosis (DVT) with a once-daily regimen of enoxaparin, rather ...
In the last 4 years, 6 phase 3 trials including a total of 27,023 patients with venous thromboemboli...
International audienceBACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fi...
International audienceBACKGROUND: Apixaban, an oral potent reversible direct inhibitor of activated ...
AbstractPurpose: The primary objective of this study was to evaluate with venography the rate of thr...
Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard ...
BACKGROUND: Vitamin K antagonists, the current standard treatment for prophylaxis against stroke and...
International audienceBACKGROUND: After stopping a 3 to 6 months course of oral anticoagulation for ...